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During 1982, surveillance identified 207 cases of Lyme disease in New York State. Cases
were clustered in two geographic areas, eastern Long Island and northern Westchester coun-
ties. Symptoms and signs of Lyme disease in cases were consistent with previous reports, with
erythema chronicum migrans (ECM) being the most frequently (77 percent) reported sign of
disease. Facial palsy was reported in a surprisingly high 18 percent ofcases. Of 160 cases whose
sera were submitted for Lyme spirochete specific IgG antibody testing, 112 (70 percent) had
titers >64, while 88 (55 percent) had titers 2 128. Positive titers were not associated with any
single sign or symptom ofdisease, but weresignificantly associated with symptom onset or tick
bite occurring during the three-month period ofJune, July, and August. We conclude that the
incidence ofLymedisease in New York is much higher than previously recognized. Inaddition,
our data suggest that a serologic test for Lyme-spirochete IgG antibody lacks sensitivity, but
can be useful in confirming the diagnosis of Lyme disease when antibody titers are high.
Since Lyme disease (LD) was initially recognized in southern Connecticut in 1975
[1], its geographic distribution has expanded to include much of the northeastern
seaboard and at least 15 states [2]. A spirochete present in Ixodes dammini ticks is
now known to be the etiologic agent of the disease [3,4]. During 1980 and 1981 the
New York State Department of Health received numerous reports of cases of LD
from physicians and county health departments. In 1982, we initiated heightened
passive surveillance to better define the distribution and epidemiologic features of
LD in New York, and to assess serologic response to the Lyme spirochete in persons
with the disease. We report here data on cases of Lyme disease occurring in 1982.
MATERIALS AND METHODS
Case Ascertainment and Reporting
Reporting ofLD cases was encouraged by several mechanisms. First, practitioners
were urged to report cases by articles on LD in the Health Department's Com-
municable Disease Newsletter, a monthlypublic health advisory sent statewide to all
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All rights of reproduction in any form reserved.practicing physicans. Second, individual letters were sent to more than 300 primary
care physicians in areas where previous case reports originated. Finally, serologic
testing for antibodies to the Lyme spirochete was offered free ofcharge to any prac-
titioner submitting sera from patients with suspected LD.
Information on reported cases was collected on a form which elicited
demographic information, tick exposure histories, and symptoms associated with
the disease.
For the purposes of this study, we defined a case as any person reported by a
physician to have Lyme disease with symptoms beginning in 1982 and who had at
least one of the following disease manifestations: erythema chronicum migrans
(ECM), aseptic meningitis (fever, headache, and stiff neck), facial nerve palsy,
and/or large joint arthritis.
Serologic Assay
Stock cultures of the I. dammini spirochete maintained in modified Kelly's
medium [5] were fixed to the wells of microtiter slides in a method previously de-
scribed [4]. Sera from persons with suspected LD were tested in pairs when two or
more specimens were obtained, or singly when one specimen was available. Both
positive and negative control specimens were tested simultaneously. Indirect im-
munofluorescence was performed using fluorescein isothiocyanate-(FITC) labeled
goat anti-human IgG serum (Cappel Laboratories, Cochranville, PA). Sera reactive
at 2 1:16 were titered to endpoint dilution.
Control Sera
As control sera, we utilized specimens obtained for premarital syphilis screening
from 329 persons who lived in two upstate counties, located more than 200 miles
from any area known to be endemic for LD. All specimens were submitted to the
New York State Department of Health Laboratories between July and September
1982. None were reactive when tested by automated reagin test (ART). Clinical
histories of LD or other illnesses on these patients were not known.
Analysis ofData
Data from case report forms and serologic results were computerized. Data from
seropositive and seronegative persons were compared, using Pearson's chi-square
contingency test. This comparison was conducted twice. Seropositives were first
defined as persons with convalescent sera collected more than two weeks after first
symptoms ofLD with titers 264. These cases were compared with seronegative per-
sons having convalescent titers <64. Seropositives were defined in the second com-
parison as persons with titers 2256, who were again compared to seronegative per-
sons with titers <64.
Persons with paired sera who demonstrated a fourfold rise in IgG antibody titer
were also compared to persons with paired sera demonstrating no fourfold rise and
no single titer 264. In this comparison, the acute serum specimen was required to be
collected within two weeks of symptom onset.
Each case was given a clinical index score ranging from 0-25, based upon their
reported symptoms. Index scores were derived from the presence of the following
symptoms: ECM (10 points), fever (2), aseptic meningitis (3), large joint arthritis
(5), facial palsy (3), and palpitations (2). Index scores were compared for sero-
positive and seronegative cases.
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RESULTS
During 1982, 207 cases of LD meeting the case definition were reported. Cases
ranged in age from one to 79 years, with a mean age of28 years. Forty-eight percent
were men, and 52 percent were women. Cases were reported from 11 upstate coun-
ties and New York City, but 84 percent were residents of either Suffolk (56 percent)
or Westchester (28 percent) counties (Fig. 1). Of 152 cases with tick bite information
recorded, 130 (86 percent) reported a tick bite prior to illness. Ofthese, 102 (79 per-
cent) occurred in Suffolk county, 25 (19 percent) in Westchester county, and 3 (2
percent) in other counties close to Suffolk or Westchester. Tick bites and ECM were
reported to occur in every month except March, but 90 (71 percent) of 126 bites and
115 (75 percent) of 154 persons with ECM reported bite or ECM onset in the three-
month period of June, July, and August (Fig. 2). In the 156 cases who had at least
one serum specimen collected and who reported a precise date of onset, symptoms
began in every month except February and March. Again, however, 101 (65 percent)
had symptoms beginning in June, July, or August (Fig. 2).
Forty-six (23 percent) of 201 cases reported hospitalization as a result of LD.
Length of stay ranged from 1-21 days, with a mean of 7.5 days. Antibiotic treat-
ment was reported to have been given to 169 (82 percent) of 205 cases. Most fre-
quently administered antibiotic therapy was penicillin (72.5 percent), followed by
tetracycline (14.4 percent) and erythromycin (2.4 percent). Other antibiotics or an-
tibiotic combinations accounted for the remaining 10.7 percent.
Symptoms and signs seen most commonly in cases included: ECM (77 percent),
myalgias (72 percent), fever (65 percent), and headache (61 percent) (Table 1).
Although joint pain was noted in 62 percent of cases, demonstrable joint swelling
was reported in only 31 percent. The kneewas affected morethantwice as frequently
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FIG. 1. Lyme disease in New York- 1982: Cases by county of residence.
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FIG. 2. 1982 Lyme disease cases.
TABLE I
Lyme Disease in New York - 1982:
Frequency of Symptoms/Signs of Lyme Disease
Symptom/Sign Number Reporting/Total %
ECM 155/201 77
Malaise 150/198 76
Myalgias 143/198 72
Fever 129/198 65
Headache 120/197 61
Stiff neck 82/191 43
Nausea 36/198 18
Facial palsy 34/191 18
Palpitations 20/183 11
Temporomandibular joint pain 16/201 8
Large joint pain 124/201 62
Knee 101/201 50
Elbow 43/201 21
Hip 40/201 20
Ankle 33/201 16
Shoulder 32/201 16
Wrist 30/201 15
Large joint swelling 63/201 31
Knee 46/201 23
Elbow 14/201 7
Hip 7/201 4
Ankle 12/201 6
Shoulder 11/201 5
Wrist 11/201 5
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as any otherjoint. Less commonly reported symptoms included facial palsy (18 per-
cent) and palpitations (11 percent).
Of 160 cases who had at least one serum specimen collected more than two weeks
after onset of symptoms, 112 (70 percent) had anti-spirochete IgG antibody titers of
2 1:64, 88 (55 percent) had titers 2 1:128, and 57 (36 percent) 2 1:256. Of the 329
control serum specimens, 11 (3.3 percent) had anti-spirochete titers of . 1:64. Of
these, ten were reactive at 1:64 and one at 1:128. No control specimens were positive
at a dilution of 1:256. Ofthe46 persons with paired seraand first specimen collected
within two weeks of symptom onset, 35 (76 percent) had fourfold rises in antibody
titer.
No single symptom of LD was significantly associated with positive IgG titers,
either at a level of 2 1:64 or at 2 1:256 (Table 2). In addition, reported cases with
high clinical index scores (many symptoms or signs suggestive ofLD) were no more
likely than persons with lower scores to have had positive titers, either at . 1:64, or
2 1:256. Similarly, cases with positive titers were no more likely to have reported
TABLE 2
Lyme Disease in New York- 1982: Features of Lyme Disease vs. Anti-Spirochete IgG Titers
Disease Feature (Number Reporting) No. of Cases with Titers pa
ECM (155)
Large joint pain (160)
Large joint swelling (160)
Knee pain (160)
Knee swelling (160)
Facial palsy (155)
Palpitations (148)
Antibiotic therapy (158)
Hospitalization (159)
Tick bite (116)
Month of bite (102)
Month of symptom
onset (139)
Present
Absent
Present
Absent
Present
Absent
Present
Absent
Present
Absent
Present
Absent
Present
Absent
Yes
No
Yes
No
Yes
No
Jun, Jul, Aug
Other
Jun, Jul, Aug
Other
<64
33
14
33
15
12
36
29
19
10
38
7
40
7
35
35
12
12
36
32
.64
80
28
65
47
39
73
50
62
27
85
25
83
10
96
91
20
27
84
60
. 256
43
13
34
23
22
35
26
51
17
40
15
39
8
47
48
7
12
45
26
NS
NS
NS
NS
NS
NS
NS
NS
NS
5 19 10 NS
18 54 45 264:X2 = 6.43;
p < 0.02
16 14 10 >256:X2 = 7.12;
p < 0.01
17 76 62 264:X2 = 21.4;
p < 0.0001
27 19 11 2256:X2 = 24.7;
p < 0.0001
aCases with titers .64 and .256 are compared to those with titers <64.
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tick bites, to have been hospitalized, or to have received antibiotics. Time delay be-
tween first symptoms of LD and start ofantibiotic therapy was also not found to be
associated with positive titers or with development ofjoint pain or swelling. Thirty-
four persons whose sera demonstrated a fourfold titer rise were no more likely than
11 non-converters to have had any single symptom or sign ofLyme disease, to have
had higher clinical index scores, to have been treated with antibiotics or hospital-
ized, or to have reported a tick bite.
Cases with positive titers more frequently reported tick bites in June, July, or
August than persons with negative titers (X2 = 6.43; p <0.02, for cases with titers
2 1:64; X2 = 7.12, p <0.01 for > 1:256.) Cases with positive titers also more fre-
quently reported symptom onset in these three months (X2= 21.4; p <0.0001, for
cases with titers > 1:649 X2= 24.7; p <0.0001, for > 1:256).
DISCUSSION
Our findings lend further support to the accumulating evidence that LD is con-
siderably more common than previously recognized. During 1980, when organized
nationwide surveillance for LD was first initiated by the Centers for Disease Control
(CDC), 226 cases from 13 states were reported, 11 of which were from New York
[6]. In 1982, CDC received 487 Lyme disease case reports, with 179 from New York
[7]. The increase in New York state cases can be attributed to three factors. First,
case reports were more intensively solicited from physicians and county health
departments. Second, serologic testing for Lyme spirochete antibodies was offered
as a free service to practitioners, which served as an adjunct to case ascertainment.
Finally, LD is probably being better recognized and diagnosed by physicians in
endemic areas.
It is unclear if the rise in reported cases of LD represents any real increase in in-
cidence or expansion ofthe endemic distribution ofthe Ixodes tick vector. However,
nearly all cases reported tick bites in areas previously known to be endemic, sug-
gesting that most of the 1982 cases resulted from better recognition of the disease.
Wherever it occurs, LD appears to be highly focal in its distribution. New York
cases occurring in 1982 also followed this pattern, being clustered in two areas: the
south shore and eastern forks of Long Island, and parts of northern Westchester
County. Both areas share several features which contribute to the substantial in-
cidence of LD: they have plentiful deer populations, they are endemic areas for Ix-
odes dammini ticks, and they have sufficient population densities to allow humans
to serve as alternate tick hosts with some frequency. While other areas ofNew York
have greater deer population density, L dammini does not occur in areas farther
north and west, accounting for the absence of cases reported from these areas.
The case definition we employed in this surveillance study was not as rigid as that
required by the CDC and utilized in previous case series. Specifically, ECM was not
required for inclusion in our case count. Wepurposely employed a less stringent case
definition for two reasons. First, some cases of LD may occur without ECM, or
where this sign is not recognized. We sought to quantitate the proportion of cases
which were suspected by physicians on clinical grounds to be LD, who had signs or
symptoms associated with the disease, but did not have ECM. Second, we wished to
assess whether or not anyparticular sign or symptom in persons suspected ofhaving
LD, including ECM, was significantly associated with a serologic response. While
some cases may have been included in our case count who did not have LD, we feel
the number of non-cases is probably small. If we used a stricter case definition
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demanding ECM, a fourfold rise in IgG titer, or a single IgG titer of > 128, 179 (86
percent) of the 207 cases would continue to be included.
Most symptoms or signs of LD were reported with frequencies consistent with
that noted in previous reports [8,9]. However, myalgias (72 percent) and facial palsy
(18 percent) occurred more frequently in our cases. The higher proportion of per-
sons with facial palsy is in part due to inclusion of persons with palsy but without
recognized ECM. Nonetheless, 21 (13.5 percent) of 155 persons with ECM reported
palsy, a figure still substantially higher than previous reports [8,10]. Thirty (88 per-
cent) of 34 persons with palsy had either ECM, a fourfold titer rise, or a single titer
> 128, suggesting that 17 percent of our cases demonstrated this sign even when a
stricter case definition is used.
Large joint swelling developed in 31 percent of patients, which is consistent with
the 35-43 percent of patients treated with antibiotics who developed arthritis in
previous reports [10,11]. Overall, more than 80 percent of our cases received an-
tibiotic therapy.
The lack of association between IgG anti-spirochete titers and the individual
symptoms or signs of LD suggests that each, considered separately, may be an
unreliable predictor of Lyme spirochete infection. The absence of association be-
tween positive titers and ECM, the clinical sign used previously to define cases of
LD, further suggests the serologic IgG assay may not be adequately sensitive to
detect a high proportion of cases. This possibility was first noted by Steere et al. [3],
who found only 22(55 percent) of40 persons with ECM as the only symptom of LD
developed fourfold IgG titer rises.
Because no single symptom of LD was associated with positivetiters, it is not sur-
prising that high clinical index scores were also not associated with positive titers. A
potential confounding variable, the presence or absence of antibiotic therapy, did
not correlate with positive titers, nor did the length of time between start of symp-
toms and initiation of antibiotic therapy. These data should be viewed with caution,
however, as cases were reported by more than 50 physicians. No attempt was made
to verify clinical diagnoses, as surveillance was the primary purpose of the study.
The usefulness of a clinical index score in predicting positive titers can perhaps best
be determined in clinical trials, where diagnosis is uniform and verifiable, and where
confounding variables such as type and timing of antibiotic therapy can be strictly
controlled.
Although the serologic test for Lyme-spirochete IgG antibody is not sensitive, our
data support previous evidence [3] that an IgG titer of > 128 is a specific marker of
Lyme spirochete exposure. Only one (0.3 percent) of 329 control sera had positive
titers at this level, compared to 88 (55 percent) of 160 reported cases.
The significant association between persons with reactive sera and tick bite and/or
symptoms beginning in June, July, and August may imply that caes reported during
these months are more likely to have LD. Previous reports have established that
nymphal Ixodes dammini are the tick stage most frequently found during these three
months [12], and that this stage is commonly infected with the Lyme spirochete [13].
Data from our study may indicate that nymphal Ixodes ticks are the most important
stage involved in human transmission of LD, as tick bite history without respect to
month was not associated with positive titers.
We conclude that the incidence ofLD in certain areas ofNew York is much higher
than previously appreciated. Although LD remains a clinical diagnosis, our data
suggest that high titers of Lyme spirochete-specific IgG antibody in patients with
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symptoms of LD can be helpful in confirming the diagnosis. However, a laboratory
test sufficiently sensitive to diagnose all cases of LD must await future refinements
or developments.
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